Explore
Validate
Learn
Western blot
ImmunocytochemistryAntibody data
- Antibody Data
- Antigen structure
- References [7]
- Comments [0]
- Validations
- Western blot [3]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- ABIN314630 - Provider product page
- Provider
- antibodies-online
- Product name
- anti-Succinate Receptor 1 (SUCNR1) (AA 100-200), (Internal Region) antibody
- Antibody type
- Polyclonal
- Description
- Immunogen affinity purified
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Epitope
- AA 100-200, Internal Region
- Vial size
- 0.1 mg
- Storage
- Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
- Handling
- Avoid freeze-thaw cycles
Submitted references Metformin ameliorates activation of hepatic stellate cells and hepatic fibrosis by succinate and GPR91 inhibition.
Succinate and its G-protein-coupled receptor stimulates osteoclastogenesis.
Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation.
The MAPK signaling pathway mediates the GPR91-dependent release of VEGF from RGC-5 cells.
Triggering the succinate receptor GPR91 enhances pressure overload-induced right ventricular hypertrophy.
ERK1/2/COX-2/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes.
Inhibition of high glucose-induced VEGF release in retinal ganglion cells by RNA interference targeting G protein-coupled receptor 91.
Nguyen G, Park SY, Le CT, Park WS, Choi DH, Cho EH
Biochemical and biophysical research communications 2018 Jan 22;495(4):2649-2656
Biochemical and biophysical research communications 2018 Jan 22;495(4):2649-2656
Succinate and its G-protein-coupled receptor stimulates osteoclastogenesis.
Guo Y, Xie C, Li X, Yang J, Yu T, Zhang R, Zhang T, Saxena D, Snyder M, Wu Y, Li X
Nature communications 2017 May 31;8:15621
Nature communications 2017 May 31;8:15621
Oncometabolite succinate promotes angiogenesis by upregulating VEGF expression through GPR91-mediated STAT3 and ERK activation.
Mu X, Zhao T, Xu C, Shi W, Geng B, Shen J, Zhang C, Pan J, Yang J, Hu S, Lv Y, Wen H, You Q
Oncotarget 2017 Feb 21;8(8):13174-13185
Oncotarget 2017 Feb 21;8(8):13174-13185
The MAPK signaling pathway mediates the GPR91-dependent release of VEGF from RGC-5 cells.
Hu J, Li T, Du S, Chen Y, Wang S, Xiong F, Wu Q
International journal of molecular medicine 2015 Jul;36(1):130-8
International journal of molecular medicine 2015 Jul;36(1):130-8
Triggering the succinate receptor GPR91 enhances pressure overload-induced right ventricular hypertrophy.
Yang L, Yu D, Fan HH, Feng Y, Hu L, Zhang WY, Zhou K, Mo XM
International journal of clinical and experimental pathology 2014;7(9):5415-28
International journal of clinical and experimental pathology 2014;7(9):5415-28
ERK1/2/COX-2/PGE2 signaling pathway mediates GPR91-dependent VEGF release in streptozotocin-induced diabetes.
Li T, Hu J, Du S, Chen Y, Wang S, Wu Q
Molecular vision 2014;20:1109-21
Molecular vision 2014;20:1109-21
Inhibition of high glucose-induced VEGF release in retinal ganglion cells by RNA interference targeting G protein-coupled receptor 91.
Hu J, Wu Q, Li T, Chen Y, Wang S
Experimental eye research 2013 Apr;109:31-9
Experimental eye research 2013 Apr;109:31-9
No comments: Submit comment
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- WB
Supportive validation
- Submitted by
- antibodies-online (provider)
- Main image
- Experimental details
- IHC
